
Summary

[0011a] In one aspect, the present disclosure provides a compound, or a pharmaceutically acceptable salt thereof, of Formula 1:



Formula I

wherein:

either (i):

$-R_1$, $-R_2$, $-R_3$, and $-R_4$ are each independently –H or deuterium;

–X is –F or –OH; and

$-R_5$ is –H, –F, or deuterium;

or (ii):

–X is –OH or –F;

R_3 is –F, –Cl, –Br or –I; and

$-R_1$, $-R_2$, $-R_4$, and $-R_5$ are each independently –H or deuterium;

wherein at least one of $-R_1$, $-R_2$, $-R_3$, $-R_4$ and $-R_5$ is –deuterium.

[0011b] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


[0011c] In another aspect, the present disclosure provides the compound as described herein, or the pharmaceutical composition as described herein, for use in therapy.

[0011d] In yet another aspect, the present disclosure provides a use of the compound as described herein, or the pharmaceutical composition as described herein, in the manufacture of a medicament for the treatment of a condition associated with hyperuricemia, wherein the condition is gout, hypertension, hypothyroidism, renal insufficiency, obesity, or diabetes.

CLAIMS

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula 1:



Formula I

wherein:

either (i):

$-R_1$, $-R_2$, $-R_3$, and $-R_4$ are each independently –H or deuterium;

–X is –F or –OH; and

$-R_5$ is –H, –F, or deuterium;

or (ii):

–X is –OH or –F;

R_3 is –F, –Cl, –Br or –I; and

$-R_1$, $-R_2$, $-R_4$, and $-R_5$ are each independently –H or deuterium;

wherein at least one of $-R_1$, $-R_2$, $-R_3$, $-R_4$ and $-R_5$ is –deuterium.

2. The compound of claim 1, wherein:


$-R_1$, $-R_2$, $-R_3$, and $-R_4$ are each independently –H or deuterium;


–X is –F or –OH; and


$-R_5$ is –H, –F, or deuterium;


wherein at least one of $-R_1$, $-R_2$, $-R_3$, $-R_4$ and $-R_5$ is –deuterium.


3. The compound of claim 1 selected from:





,



,



,



,



,



,


,



,



,



,



,



,




,


,



,


,


, and


.

4. The compound of claim 1 wherein the compound is:



.

5. A pharmaceutical composition comprising the compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5, further comprising a xanthine oxidase inhibitor.

7. The compound of any one of claims 1-4, or the pharmaceutical composition of claim 5, for use in therapy.

8. Use of the compound of any one of claims 1-4, or the pharmaceutical composition of claim 5, in the manufacture of a medicament for the treatment of a condition

associated with hyperuricemia, wherein the condition is gout, hypertension, hypothyroidism, renal insufficiency, obesity, or diabetes.